Global Locations

Daclatasvir 13C2D6



Chemical Properties of 'Daclatasvir 13C2D6'

CAT No. :

CS-O-11957
CAS Registry No. : 1009119-64-5(Unlabeled)
Category : Isotope Labelled Compounds
Molecular Weight: 746.90
Molecular Formula : C₃₈¹³C₂H₄₄D₆N₈O₆



OTHER INFORMATION of 'Daclatasvir 13C2D6'
Purity : Not less than 90%
Therapeutic : Antiretroviral / Anti-HIV
Isotopic Enrichment : Not less than 95%
Purity : Not less than 90%
Therapeutic : Antiretroviral / Anti-HIV
Isotopic Enrichment : Not less than 95%
IUPAC Name :methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
Applicationnotes :"Labeled Daclatasvir , intended for use as an internal standard for the quantification of Daclatasvir by GC- or LC-mass spectrometry."
Synonym :Not available
References :"Hamann, Lawrence G, (2010); Bell, Thomas W, (2010)"
Smileys :O=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(O[13C]([2H])([2H])[2H])=O)=O)N5)C=C4)C=C3)N2)CCC1)[C@H](C(C)C)NC(O[13C]([2H])([2H])[2H])=O
Appearance :Off white to white powder
Solubility :Freely soluble (>700 mg/mL)
Use Classification :Human drugs -> Daklinza -> EMA Drug Category
Hazard Class :Skin Sens. 1B (100%)
EC Number :816-965-3
UNII :LI2427F9CI
NCI Thesaurus Code :C114981
MeSH Entry Terms :BMS-790052
Other Synonyms :Daclatasvir
Removed Synonyms :daclatasivr
Toxicity Summary :The most common adverse effects experienced in patients undergoing daclatasvir and sofosbuvir therapy include headache, fatigue, nausea and diarrhea. Similar side effects are seen when ribavirin is added, in addition to rash, insomnia, anemia, dizziness and somnolence. There are postmarketing cases that link serious symptomatic bradycardia with Daklinza when used in conjunction with sofosbuvir and amiodarone. Coadministration of these three drugs is not recommended unless there are no other alternatives.
Hepatotoxicity :In large randomized controlled trials, daclatasvir was not associated with serum enzyme elevations during therapy. A difficulty in assessing side effects of daclatasvir and other anti-HCV agents, however, was that they are never used as monotherapy, but were also combined with agents active against other HCV targets, such as the viral protease (NS3) or polymerase (NS5B). Daclatasvir was also commonly used in combination with the more traditional agents used for hepatitis C, such as peginterferon and ribavirin, both of which have prominent adverse effects. In combination with asunaprevir (an HCV protease inhibitor), daclatasvir was associated with serum ALT elevations in 3% to 11% of patients and with several instances of acute hypersensitivity and hepatitis, some of which were severe. The cause of the hypersensitivity reaction, however, appeared to be asunaprevir. In combination with sofosbuvir, daclatasvir was not associated with serum enzyme elevations or with clinically apparent liver injury.
Protein Binding :Daclatasvir is highly protein bound (99%).
Exact Mass :738.38533134
InChI :InChI=1S/C40H50N8O6/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52)/t31-,32-,33-,34-/m0/s1
InchIKey :FKRSSPOQAMALKA-CUPIEXAXSA-N
Canonical SMILES :CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC
Isomeric SMILES :CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
Product Description :Daclatasvir is a member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C. It has a role as a nonstructural protein 5A inhibitor and an antiviral drug. It is a member of biphenyls, a member of imidazoles, a carbamate ester, a carboxamide and a valine derivative. It is a conjugate base of a daclatasvir(2+).
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 15-Aug-2022
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Daclatasvir



Medical use




This page contains information about Daclatasvir 13C2D6 , Daclatasvir 13C2D6 cas, Daclatasvir 13C2D6 synthesis, Daclatasvir 13C2D6 suppliers

What is Daclatasvir 13C2D6 ?
Daclatasvir 13C2D6 falls under Isotope Labelled Compounds of Daclatasvir."Labeled Daclatasvir , intended for use as an internal standard for the quantification of Daclatasvir by GC- or LC-mass spectrometry."
What is the CAS Number of Daclatasvir 13C2D6?
The CAS Number of Daclatasvir 13C2D6 is 1009119-64-5(Unlabeled)
Who are the suppliers of Daclatasvir 13C2D6?
CLEARSYNTH is a worldwide supplier of Daclatasvir 13C2D6

Related compounds of Daclatasvir 13C2D6

Looking for a discounted price or need more info for 'Daclatasvir 13C2D6 (CS-O-11957)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Daclatasvir 13C2D6 (CS-O-11957)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.